Table 1.

Recommendation for evaluation and reporting Immune Exclusion in cancer samples.

	Recommendation	Notes
Tissue sample	Surgical resection specimen or core needle biopsy with multiple cores	Locations of metastasis may impact the immune phenotype
Analysis method	Immunohistochemistry or immunofluorencence with a marker to differentiate stroma from tumor parenchyma	Gene signatures should be derived from a sufficiently large dataset of tumors with spatial characterization
Immune cells analyzed	CD8+ T lymphocytes	Evaluating T cell activation/exhaustion markers and other immune cell subsets add additional information of the TME contexture
Compartments analyzed	Tumor parenchyma
	Tumor Stroma
Measured value	Cell densities (cells/mm3)
	Ratio of parenchyma/stroma
Cut-off for definition	Based on clinical outcome variables as available	These include overall survival, progression-free or disease-free survival, and response to therapy
Tumor heterogeneity	Evaluate multiple areas of tumor	Report degree of heterogeneity